Skip to content
Menu

Nurix Therapeutics, Inc. NRIX

Full chart Compare
Set alert

Price alert · NRIX

All alert types
12.85 USD -0.75 (-5.51%)

Regular-session close

12.70 -0.15 -1.17%

After hours · Nov 20, 4:18 PM ET

12.83 Day range 13.67
12.83 52-week range 28.23
YTD
-32.26%
1 year
-16.18%

5D -2.63 (-16.86%)

131415MonTueWedThuFri12.97
Market cap
1.40B
Revenue (ttm)
701.94M
Profit margin
42.01%
EPS (ttm)
2.43
Shares out
109.25M
P/E ratio
5.29
Forward P/E
-10.07
YTD return
-32.26%
1-year return
-16.18%
50-day average
22.31
Volume
2.43M
Avg volume
2.46M
Open
13.40
Previous close
13.60
Day's range
12.83 – 13.67
52-week range
12.83 – 28.23
Beta
1.78
Analysts
Strong Buy
Price target
33.50 (+160.7%)
Earnings date
Jan 27, 2027

Key statistics

200-day average
20.08
Enterprise value
502.87M
Price / sales
2.00
Price / book
1.45
Revenue growth
8426.30%
Free cash flow
233.34M
Total cash
1.05B
Total debt
65.33M
Return on equity
43.99%
Short % of float
17.52%

Fundamental scorecard

16 of 25 checks passed on NRIX’s reported financials

ValueGrowthProfitabilityHealthDividend

16of 25 checks passed

  • Value 4 of 5
  • Growth 3 of 5
  • Profitability 4 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Aug 31, 2026.

Financials — quick view

All financials
NRIX Revenue — quarterly 673.06M
NRIX Net income — quarterly 549.81M
NRIX EPS — quarterly 4.93

Earnings

NRIX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 27, 2027Nov 30, 2026-0.46———
Oct 12, 2026Aug 31, 2026-0.600914.73+5.33+887.14%
Jul 9, 2026May 31, 2026-0.72288-0.81-0.09-12.05%
Apr 8, 2026Feb 28, 2026-0.76-0.79-0.03-3.95%
Jan 28, 2026Nov 30, 2025-0.84-0.82+0.02+2.38%
Oct 9, 2025Aug 31, 2025-0.84-1.03-0.19-22.62%

Upgrades / downgrades

NRIX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 4, 2026Wells FargomainEqual-WeightEqual-Weight
Oct 16, 2026HC Wainwright & Co.mainBuyBuy
Oct 13, 2026RBC CapitalmainOutperformOutperform
Oct 13, 2026OppenheimermainOutperformOutperform
Oct 13, 2026Truist SecuritiesmainBuyBuy
Oct 13, 2026BairdmainOutperformOutperform

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
nurixtx.com

News

Your note

Sign in to keep a note on NRIX — it syncs with the Stock Master app.

Insider holders

NRIX insider holders
InsiderRelationLatest transactionDateShares held
GREGORY JULIA PAIGEDirectorSaleOct 13, 202610,750
HANSEN GWENN MOfficerSaleNov 1, 2026123,452
RING CHRISTINEOfficerSaleNov 2, 20264,406
VAN HOUTE JOHANNES DChief Financial OfficerSaleNov 3, 202642,745

Institution ownership

NRIX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.06%8,801,242113.10MSep 29, 2026
Redmile Group, LLC7.23%7,901,085101.53MSep 29, 2026
Vestal Point Capital, LP6.43%7,025,00090.27MSep 29, 2026
Deep Track Capital, Lp5.49%6,000,00077.10MSep 29, 2026
Perceptive Advisors Llc4.92%5,371,62969.03MSep 29, 2026
Morgan Stanley4.80%5,246,51167.42MSep 29, 2026

Fund ownership

NRIX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.00%3,273,94342.07MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.28%2,490,24632.00MSep 29, 2026
ARK ETF Trust-ARK Genomic Revolution ETF2.13%2,329,80129.94MOct 30, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.01%2,192,56228.17MSep 29, 2026
SmallCap World Fund Inc1.59%1,739,33522.35MSep 29, 2026
MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund1.19%1,297,89316.68MJun 29, 2026